Comparative study of zinc levels in benign and malignant lesions of the prostate

Goel, Tanmaya; Sankhwar, SN

doi:10.1080/00365590500368922

Cited by 28 publications

(23 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although low plasma zinc concentrations have been reported in patients with prostate carcinoma (0.6+/−0.03 μg/ml in patients with prostatic malignancies vs. 0.95+/−0.1 μg/ml in healthy controls), 38 this is not the likely culprit for a decreased zinc accumulation in malignant prostate cells. Instead, prostate cancer modulates the specialized mechanisms that are required for both zinc uptake and release.…”

Section: Zinc Transportmentioning

confidence: 83%

Zinc and zinc transporters in prostate carcinogenesis

et al. 2013

View full text Add to dashboard Cite

The healthy human prostate accumulates the highest level of zinc of any soft tissue in the body. This unique property is retained in BPH, but is lost in prostatic malignancy, which implicates changes in zinc and its transporters in carcinogenesis. Indeed, zinc concentrations diminish early in the course of prostate carcinogenesis, preceding histopathological changes, and continue to decline during progression toward castration-resistant disease. Numerous studies suggest that increased zinc intake might protect against progression of prostatic malignancy. Despite increased dietary intake, zinc accumulation might be limited by the diminished expression of zinc uptake transporters, resulting in decreased intratumoural zinc levels. This finding can explain the conflicting results of various epidemiological studies evaluating the role of zinc supplementation on primary and secondary prostate cancer prevention. Overall, more research into the mechanisms of zinc homeostasis are needed to fully understand its impact on prostate carcinogenesis. Only then can the potential of zinc and zinc transport proteins be harnessed in the diagnosis and treatment of men with prostate cancer.

show abstract

Section: Zinc Transportmentioning

confidence: 83%

Zinc and zinc transporters in prostate carcinogenesis

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Although serum Zn levels are considered a poor indicator of Zn status, serum Zn levels are generally low in patients with multiple cancers [30], including patients with squamous esophageal cancer [31], malignant prostate cancer [32], ovarian cancer [33], and cancers of the gallbladder [34], lung [35], colon, head and neck [36], and bronchus [35]. Multiple studies also show a relationship between low plasma Zn levels and the risk for developing breast cancer [37,38,39], prompting the suggestion that plasma Zn levels can be used as a prognostic as well as a therapeutic marker for breast cancer [40,41,42].…”

Section: Comparative Plasma and Tumor Zinc Levels And Breast Cancementioning

confidence: 99%

Cellular Mechanisms of Zinc Dysregulation: A Perspective on Zinc Homeostasis as an Etiological Factor in the Development and Progression of Breast Cancer

2012

View full text Add to dashboard Cite

Worldwide, breast cancer is the most commonly diagnosed cancer among women and is the leading cause of female cancer deaths. Zinc (Zn) functions as an antioxidant and plays a role in maintaining genomic stability. Zn deficiency results in oxidative DNA damage and increased cancer risk. Studies suggest an inverse association between dietary and plasma Zn levels and the risk for developing breast cancer. In contrast, breast tumor biopsies display significantly higher Zn levels compared with normal tissue. Zn accumulation in tumor tissue also correlates with increased levels of Zn importing proteins. Further, aberrant expression of Zn transporters in tumors correlates with malignancy, suggesting that altered metal homeostasis in the breast could contribute to malignant transformation and the severity of cancer. However, studies have yet to link dysregulated Zn transport and abnormal Zn-dependent functions in breast cancer development. Herein, we summarize studies that address the multi-modal role of Zn dyshomeostasis in breast cancer with respect to the role of Zn in modulating oxidative stress, DNA damage response/repair pathways and cell proliferation/apoptosis, and the relationship to aberrant regulation of Zn transporters. We also compare Zn dysregulation in breast tissue to that of prostate, pancreatic and ovarian cancer where possible.

show abstract

“…There was a highly statistically significant difference in plasma Zinc level between patients with benign and malignant prostatic disease. 5 The effect of metastasis of carcinoma of the prostate on plasma Zinc levels was not significant(p>0.05). They concluded that determination of serum zinc levels can be used as a diagnostic and screening tool and may lead to the formulation of methods in which Zinc is used to evaluate prostatic pathology.…”

Section: Methodsmentioning

confidence: 98%

Serum Zinc, Total & Free PSA, Free/Total PSA Ratio and Prostate Cancer Association: A Case Control Study

Rahman

Ashrafi

Choudhury

et al. 2013

Anwer Khan Mod Med Coll J

View full text Add to dashboard Cite

digital examination (PRDE), Ultrasonogram (USG) of Prostate and prostatic biopsy. Many research already done world wide on Zinc, total & free PSA and ratio of free and total PSA and prostate cancer association are conflicting and opposing. Available literature search reveal no work was done on these in Bangladesh. With this background the present study was undertaken to observe if there is any association of serum Zinc level with histologically diagnosed prostatic

show abstract

Comparative study of zinc levels in benign and malignant lesions of the prostate

Abstract: There appears to be a strong correlation between plasma zinc levels and various prostatic diseases. Therefore, the determination of zinc levels can be used as a diagnostic or screening tool and may lead to the formulation of methods in which zinc is used to evaluate prostatic pathology.

Cited by 28 publications

References 12 publications

Zinc and zinc transporters in prostate carcinogenesis

Zinc and zinc transporters in prostate carcinogenesis

Cellular Mechanisms of Zinc Dysregulation: A Perspective on Zinc Homeostasis as an Etiological Factor in the Development and Progression of Breast Cancer

Serum Zinc, Total & Free PSA, Free/Total PSA Ratio and Prostate Cancer Association: A Case Control Study

Contact Info

Product

Resources

About